NUCLIDIUM Sees Copper Isotopes as Future of Radiopharmaceuticals, Raises CHF 79M to Advance Clinical Development

NUCLIDIUM recently closed a CHF 79 million (EUR 84 million, $99 million) Series B financing round to advance its copper-based radiopharmaceutical platform for cancer diagnostics and therapeutics145.

The company's platform leverages copper-61 for PET imaging and copper-67 for therapy, offering a theranostic pairing (diagnosis and treatment) for various cancers, including metastatic prostate cancer, neuroendocrine tumors, and breast cancer134.

Initial clinical data suggest that NUCLIDIUM's Cu-NuriPro™ imaging agent detects more prostate cancer lesions than existing approved radioactive diagnostic agents in 50% of patients4.

NUCLIDIUM's CEO, Leila Jaafar, highlighted the significant safety, efficacy, and manufacturing advantages of copper isotopes compared to other radioisotopes, supporting the company's belief that copper could become the leading isotope in radiopharma2.

With the new funding, NUCLIDIUM plans to expand its production and manufacturing capacity, strengthen collaborations with hospitals and academic centers in Europe and North America, and broaden its pipeline to include new cancer targets, especially in women's health13.

Sources:

1. https://www.globenewswire.com/news-release/2025/07/10/3113042/0/en/NUCLIDIUM-Closes-CHF-79-Million-EUR-84-Million-Series-B-Financing-to-Advance-Clinical-Development-of-its-Copper-based-Radiopharmaceutical-Platform.html

2. https://firstwordpharma.com/story/5980185

3. https://nuclidium.com/nuclidium-closes-chf-79-million-eur-84-million-series-b-financing-to-advance-clinical-development-of-its-copper-based-radiopharmaceutical-platform/

4. https://www.fiercebiotech.com/biotech/radiopharma-biotech-raises-99m-series-b-test-copper-based-diagnostic-therapeutic-combo

5. https://www.startupticker.ch/en/news/chf-79-million-to-advance-nuclidium-s-copper-based-radiopharmaceutical-platform